ClinicalTrials.gg
CompletedNCT05490017Updated Mar 1, 2023

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

A Phase 1 interventional study of KP104 and Placebo in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Kira Pharmacenticals (US), LLC.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by Kira Pharmacenticals (US), LLC. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Dec 2020, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Hemoglobinuria, Paroxysmal · Australia.

Enrollment
6th of 12
80 · median 80
Started
2020
the only one that year
Phase 1
Only one
of the 15
Registered
12th of 15
by date
Lead sponsor
1 of 15
Kira Pharmacenticals (US), LLC.

Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is the only one in phase 1, and was the 12th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

2 of the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of KP104 and Part 2, multiple ascending dose (MAD).

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • KP104
  • Paroxysmal Nocturnal Hemoglobinuria
  • Single ascending Dose
  • Multiple Ascending Dose
  • First in Human
  • Complement Inhibitor
  • Healthy participants
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight of > 40 kilograms (kg) and \< 120 kg at Screening.
  • In good general health, determined by no findings in the opinion of the Investigator from medical history, physical examination, 12-lead , clinical laboratory findings, and vital signs at Screening and Check-in.
  • , hematocrit, white blood cell count, , and count results within the normal range at the Screening Visit; participants with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment. Tests may be repeated at the discretion of the Investigator to confirm abnormalities.
  • based on the Cockcroft-Gault equation of >= 80 milliliters per minute (ml/min).
  • Females of and males must practice effective from Screening until 28 days after the end of study (EOS) visit.
  • Females of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug; for subjects, a blood sample will also be tested for follicle stimulating hormone to confirm post-menopausal status.

Exclusion criteria

Exclusion Criteria:

  • Any underlying illness in the opinion of the Investigator.
  • Any history or sign of significant chronic active or recurrent infection, or screening laboratory evidence consistent with a significant chronic active or recurrent infection requiring treatment with antibacterials, antivirals, or antifungals.
  • Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibacterials, antivirals, or antifungals.
  • History of clinically significant hematologic or bone marrow disease or blood dyscrasias.
  • History of meningococcal infection.
  • History of tuberculosis.
  • History of asplenia (functional or anatomical).
  • Prior exposure to KP104.
  • Known allergy to penicillin antibiotics or history of allergy or to required prophylactic antibiotic therapy to be used during the study.
  • Known or suspected complement deficiency during screening.
  • Positive serology for virus (HBV), virus (HCV) or (HIV) at Screening.
  • History of drug or alcohol abuse within 1 year of Screening in the opinion of the investigator, or a positive test for drugs of abuse or alcohol at Screening or Check-in.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Part 1: Single Ascending Dose Cohort 1

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 2

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 3

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 4

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 5

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 6

    Drug: KP104

  • Experimental
    Part 1: Single Ascending Dose Cohort 7

    Drug: KP104

  • Experimental
    Part 2: Multiple Ascending Dose Cohort 1

    Drug: KP104

  • Experimental
    Part 2: Multiple Ascending Dose Cohort 2

    Drug: KP104

  • Experimental
    Part 2: Multiple Ascending Dose Cohort 3

    Drug: KP104

  • Placebo comparator
    Part 1: Placebo

    Drug: Placebo

  • Placebo comparator
    Part 2: Placebo

    Drug: Placebo

Interventions

  • DrugVensobafusp alfaStudies of Vensobafusp alfaVensobafusp alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.

  • DrugPlacebo

    Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).

06

What researchers measure

Primary outcomes

  1. Number of participants reporting Treatment Emergent Adverse Events (TEAEs)

    An Adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. A TEAE is defined as any AE that started or worsened in severity on or after the first dose of study treatment.

    Time frame: Up to Day 85

  2. Number of participants reporting Treatment Emergent Serious Adverse Events (TESAEs)

    A TESAE is defined as any AE that started or worsened in severity on or after the first dose of study treatment.

    Time frame: Up to Day 85

  3. Number of participants with Dose-limiting toxicities (DLT)

    A DLT is defined as any adverse event considered by the investigator to be KP104-related with a severity greater than or equal to (\>=) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 3 which also represents a shift from baseline clinical status of \> 1 NCI CTCAE grade. A hypersensitivity/administration reaction occurring with a severity of Grade 2 despite the use of pre-medications will also be designated as a DLT.

    Time frame: Up to Day 85

  4. Number of participants reporting AEs of Special interests (AESIs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. Number of participants with AESIs including infections and local or systemic administration reactions will be assessed.

    Time frame: Up to Day 85

Secondary outcomes

  1. Maximum concentration (Cmax) of KP104

    Time frame: Up to Day 29

  2. Area under the concentration-time profile (AUC) of KP104

    Time frame: Up to Day 29

  3. Change from baseline in total and free serum C5 levels

    Time frame: Baseline and up to Day 29

  4. Change from baseline in rabbit red blood cell (RBC) assay

    Time frame: Baseline and up to Day 29

Other outcomes

  1. Changes in serum free C5 levels to Minimum concentration (Cmin) correlation

    Time frame: Baseline and up to Day 29

  2. Changes in serum free C5 levels to AUC correlation

    Time frame: Baseline and up to Day 29

  3. Changes in C3b activity to Cmax correlation

    Time frame: Baseline and up to Day 29

  4. Changes in C3b activity to Cmin correlation

    Time frame: Baseline and up to Day 29

  5. Changes in C3b activity to AUC correlation

    Time frame: Baseline and up to Day 29

  6. Changes in rabbit RBC lysis to Cmax correlation

    Time frame: Baseline and up to Day 29

  7. Changes in rabbit RBC lysis to Cmin correlation

    Time frame: Baseline and up to Day 29

  8. Changes in rabbit RBC lysis to AUC correlation

    Time frame: Baseline and up to Day 29

  9. Immunogenicity of KP104

    Time frame: Up to Day 29

  10. Maximum tolerated dose (MTD) of KP104

    Time frame: Up to Day 29

  11. Optimal biologic dose (OBD) of KP104

    Time frame: Up to Day 29

  12. Number of participants with clinically significant changes in laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs

    Time frame: Up to Day 29

  13. Changes in serum free complement component C5 levels to Cmax correlation

    Time frame: Baseline and up to Day 29

  14. Dose optimization of KP104

    Time frame: Up to Day 29

  15. Systemic clearance (Cl) of KP104

    Time frame: Up to Day 29

  16. Elimination half-life (t½) of KP104

    Time frame: Up to Day 29

  17. Change from baseline in complement component of C3b activity assay

    Time frame: Baseline and up to Day 29

  18. Absolute bioavailability of KP104 administered SC (F)

    Time frame: Up to Day 29

  19. Change from baseline in Factor H (FH) serum levels

    Time frame: Baseline and up to Day 29

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, Australia
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in May 2022, 16 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Aug 5, 2022
StartActual
Dec 30, 2020
Primary completionActual
May 4, 2022
CompletionActual
Sep 2, 2022
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05490017
Lead sponsor
Kira Pharmacenticals (US), LLC.
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Dec 30, 2020
Primary completion
May 4, 2022
Completion
Sep 2, 2022
Last update
Mar 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vensobafusp alfa

Start the discussion